(Q53348639)
Statements
A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease. (English)
D Koper
E Ruether
R Husmann
E Kinzler
E Diabl
D Klingler
J Spatt
R Ritter
R Schmidt
Z Taneri
W Winterer
M Rainer
H Moessler
1 September 2001
16
5
253-263